Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## **FEE TRANSMITTAL** for FY 2001

Patent fees are subject to annual revision.

	<u> </u>	
Application Number	09/760,364	RECEIVED
Filing Date	January 12, 2001	TILOL.
First Named Inventor	Lehmann, Jurgen M.	JUN 1 1 ZUW
Examiner Name	Joseph Murphy	TICH CENTER 1600/2900
Group Art Unit	1646	TECH CENTER TOPULZAGE

TOTAL AMOUNT OF PAYMENT

200

18781-004110 Attorney Docket No

Ac Nu De Ac Na	posit count imber posit count ime		indicate	ommissio ed fees a	oner is hereby au and credit any ov	ithorized to charge	3. AD0	DITIONAL	FEES			
De Ad Nu De Ad	posit count imber posit count ime			ed fees a	and credit any ov	er payments to						
Ac Nu De Ac Na	count imber eposit ecount ime		20-1			- 4-7	Large	Entity	Small	Entity		
Ac Nu De Ac Na	count imber eposit ecount ime		20-1				Fee	Fee	Fee	Fee	Fee Description	Fee Paid
De Ad Na	imber eposit count ime		20-1	<b>430</b>			Code	(\$)	Code	(\$)	Surcharge - late filing fee or oath	Faiu
Ac Na	count ime		Account 20-1430				105 127	130	205	65		
Ac Na	count ime							50	227	25	Surcharge - late provisional filing fee or cover sheet	
Na	me	Deposit Account Townsend and Townsend and Crew LLP						130	139	130	Non-English specification	<u> </u>
$\geq$	1 Charo	Name						2,520	147	2 520	For filing a request for reexamination	
	Charge Any Additional Fee Required Under 37 CFR 1 16 and 1.17						112	920*	112	920°	Requesting publication of SIR prior to Examiner action	
Applicant claims small entity status See 37 CFR 1 27							113	1,840*	113	1.840*	Requesting publication of SIR after Examiner action	
2. Payment Enclosed:							115	110	215	55	Extension for reply within first month	
☐ Check ☐ Credit card ☐ Money ☐ Other					116	400	216	20G	Extension for reply within second month	200		
Order							117	920	217	460	Extension for reply within third month	
FEE CALCULATION  1. BASIC FILING FEE							118	1,440	218	720	Extension for reply within fourth month	
				= Entity			128	1,960	228	980	Extension for reply within fifth month	
arge	Fee	•			Fee Description		119	320	219	160	Notice of Appeal	
ee ode	(\$)			\$)	ee Description	Fee Paid	120	320	220	160	Filing a brief in support of an appeal	L
01	740				Utility filing fee		121	280	221	140	Request for oral hearing	
06	330	2	:06	165 [	Design filing fee		138	1,510	138	1,510	Petition to institute a public use proceeding	
07	510				Plant filing fee		140	110	240	55	Petition to revive – unavoidable	
08	740				Reissue filing fee		141	1,280	241	640	Petition to revive – unintentional	
14	160	J 2	214 8	30 F	Provisional filing	ice	142	1,280	242	640	Utility issue fee (or reissue)	
			SUE	BTOTAL	. (1)	(\$)	143	460	243	230	Design issue fee	
							144	620	244	310	Plant issue fee	
. EX	TRA C	LAIM	FEES			· · · · · · · · · · · · · · · · · · ·	122	130	122	130	Petitions to the Commissioner	
			-20**	-	Extra Fei Claims bel	e from Fee ow Paid	123	50	123	50	Petitions related to provisional applications	
tal Cl Jepen			-3		^		126	180	126	18C	Submission of Information Disclosure Stmt	
aims iltiple ipend	ent				x [	=	581	40	581	40	Recording each patent assignment per property (times number of properties)	
arge ee	E	ntity	Small Fee	Entity Fee			146	740	246	370	Filing a submission after final rejection (37 CFR § 1,129(a))	
ree Code 103	(	-ee \$) 18	Code 203	( <b>\$</b> )	Fee Descript Claims in exc		149	740	249	370	For each additional invention to be examined (37 CFR § 1 129(b))	
102		34	202	42		claims in excess of 3	179	740	279	370	Request for Continued Examination (RCE)	i
104		280	204	140		ndent claim, if not paid						
09		34	209	42	** Reissue ind original paten	169	900	169	900	Request for expedited examination of a design application		
** Reissue claims in excess of 20 and over original patent					Other fee (specify)							
				su	JBTOTAL (2)	(\$)		The Commissioner is authorized to charge any additional fees to the above noted Deposit Account				
							*Redi	ced by B	asic Filii	ng Fee P	aid SUBTOTAL (3) (\$)200	

SUBMITTED BY		Complete (if applicable)
	Lugenia Garrett- Vackowski RegistroponVo (Attorney/Agen) 37,330	Telephone 925-472-5000
Signature	Quarnia Shull Walnulli	Date 5:24:02

ormation on this form may become public. Credit card information should not be s form. Previde credit card information and authorization on PTO-2038.

Burden Hour Statement. This form is estimated to take of hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Washington, DC 20231. WC 9041832. V1

COPY OF PAPEH. ORIGINALLY FILED

OPY PAPERS ORIGINALLY FILED

# 11 20/18/02

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231

on 5-24-02

Anda shaffer

RECEIVED<sup>18781-004110</sup>

JUN 1 1 2002

**TECH CENTER 1600/2900** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jurgen M. Lehmann, et al.

Application No.: 09/760,364

Filed: January 12, 2001

For: CAR MODULATORS:

SCREENING AND TREATMENT OF

**HYPERCHOLESTEROLEMIA** 

Examiner: Joseph Murphy

Art Unit: 1

1646

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Restriction Requirement mailed March 15, 2002, Applicants elect, with traverse, to prosecute the subject matter of Group I, claims 1-41, drawn to a method for identifying a therapeutic agent for use in treating a CAR-mediated disorder. In response to the Species Election, Applicants elect the species of Invention I wherein the DNA binding domain is substantially identical to a DNA binding domain in CAR. Applicants also elect the species of Invention I wherein the CAR ligand is 5β-pregnan-3,20-dione.

The foregoing election is made with traverse. Examination of the subject matter recited in the claims of Groups I-V would not place a substantially greater burden on the Examiner. Accordingly, Applicants respectfully request the Examiner to withdraw the Restriction Requirement and to consider claims 1-59 together in the present case.

Jurgen M. Lehmann, et al. Application No.: 09/760,364

Page 2

If the Examiner has any questions regarding Applicants' election, or if the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at (925) 472-5000.

Respectfully submitted,

Eugenia Garrett-Wackows

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300

EGW:lls

WC 9039191 v1